← Issue №20/ week of Nov 15, 2026/Pancreas/Biliary

Natural history and pancreatic cancer risk in PRSS1-associated hereditary pancreatitis: a nationwide cohort.

From GI Signals issue №20: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Pancreas/Biliary retrospective · n=455 · Nov 11, 2026 · Clin Gastro Hep · IF 16.2

Natural history and pancreatic cancer risk in PRSS1-associated hereditary pancreatitis: a nationwide cohort.

New evidencechronic pancreatitispancreatic cancerepidemiologypediatric
Clinical takeawayConsider lifelong follow-up and pancreatic cancer surveillance in PRSS1-associated hereditary pancreatitis, with strategies that account for risk rising with age and wide variation in age at diagnosis; diabetes was associated with higher cancer risk (HR 6.8).
What it foundPRSS1-associated hereditary pancreatitis carries a cumulative pancreatic ductal adenocarcinoma risk of 2.0% by age 50 and 5.9% by age 60, with a standardized incidence ratio of 32.2 (95% CI, 19.4-50.3).
ContextConfirms and quantifies the high pancreatic cancer risk in a nationwide French cohort (455 carriers with follow-up): penetrance 77.6%, median symptom onset 12.5 years, and cancer at a median age of 63.8 years.
Emergingsuggested applicable standard· American College of Gastroenterology, 'ACG Clinical Guideline: Chronic Pancreatitis' (Gardner TB et al., Am J Gastroenterol 2020;115(3):322-339). DOI 10.14309/ajg.0000000000000535, PMID 32022720.

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Confirm chronic pancreatitis on CROSS-SECTIONAL IMAGING, CT for late calcific disease, MRI/MRCP (with secretin where available) for earlier ductal and parenchymal change, EUS an acceptable alternative; per ACG 2020, "Diagnosis is made usually on cross-sectional imaging, with modalities such as endoscopic ultrasonography and pancreatic function tests playing a secondary role". Fecal elastase does NOT confirm chronic pancreatitis: it is a test of exocrine FUNCTION and is the appropriate initial test for the exocrine pancreatic insufficiency (EPI) that chronic pancreatitis causes, a consequence of the disease, not the diagnosis of it. A normal fecal elastase does not exclude chronic pancreatitis and a low one does not establish it. Per AGA 2023, fecal elastase must be run on a semi-solid or solid stool specimen; below 100 mcg/g is good evidence of EPI and 100-200 mcg/g is indeterminate (below 200 mcg/g is the cutoff commonly used to screen). Then manage with smoking and alcohol cessation, PERT for exocrine insufficiency titrated to symptoms, fat-soluble vitamin and bone surveillance, and individualized type 3c diabetes control, considering insulin early in patients with marked hyperglycemia or symptoms of insulin deficiency. Treat pain with a stepwise ladder from scheduled acetaminophen and neuromodulators to EUS-guided celiac plexus block and endoscopic/surgical intervention, referring early for surgery per ESCAPE 2020 in candidates with main pancreatic duct obstruction. Screen for PDAC per lifetime risk and pursue etiologic workup via TIGAR-O v2, including genetic testing and autoimmune pancreatitis evaluation.

American College of Gastroenterology, 'ACG Clinical Guideline: Chronic Pancreatitis' (Gardner TB et al., Am J Gastroenterol 2020;115(3):322-339). DOI 10.14309/ajg.0000000000000535, PMID 32022720. · reviewed 2026-07-21 ↗
Cléry G … Rebours V · Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association · IF 16.2 · PubMed ↗Permalink
← Read the whole of issue №20 Every paper GI Signals surfaces gets a page like this one. All issues